Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07075718

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Glaucoma Eye Diseases Glaucoma, Open-Angle Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Glaukos Investigative Site, Grand Junction, Colorado, United States

Loading trial locations.

About this study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Compared to Timolol Ophthalmic Solution 0.5% Administered Twice Daily in Subjects with Open-Angle Glaucoma or Ocular Hypertension

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of open-angle glaucoma or ocular hypertension in the study eye

Exclusion criteria

  • Prior incisional glaucoma surgery in the study eye
  • Prior argon laser trabeculoplasty (ALT) in the study eye
  • Prior minimally invasive glaucoma (MIGS) surgery in the study eye

Treatment and study plan

Gen 2 Travoprost Intracameral Implant

Drug

travoprost

Other names: Gen 2 Travoprost Intraocular Implant

Timolol eye drops 0.5%

Drug

timolol 0.5%

Other names: Timolol maleate ophthalmic solution, 0.5%

Sham Procedure

Procedure

sham implant administration

placebo eye drops

Other

artificial tears

Primary outcomes

  1. Intraocular pressure (IOP)

    Time frame: 3 months

    Change from baseline in diurnal IOP in the study eye at 8AM and 10AM at each of Day 11, Week 6, and Month 3 visits

Study contacts

Contact information is provided by the study sponsor or research team.

Study Director

CONTACT

[email protected]

949-739-8749

Sponsors and collaborators

Lead sponsor

Glaukos Corporation

Industry

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2032
First posted
Jul 20, 2025
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.